• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database

  • Print
  • Share
  • E-mail
-

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


           

LAL/LDD Postmarket RCT


Suggest Enhancement / Report Issue | export reports to excelExport to Excel
General
Study Status Progress Adequate
Application Number P160055 / PAS001
Date Current Protocol Accepted 03/10/2021
Study Name LAL/LDD Postmarket RCT
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group Concurrent Control
Analysis Type Analytical
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Design Description A two-phased study (Phase A and B) will be conducted that evaluate the following two safety questions: (1) What is the rate of endothelial cell density loss (ECL) for patients with the RxSight LAL/LDD? (2) What is the rate of retinal damage caused by UV treatment with the LDD that may not be detected by routine post-operative testing?

Study Population Description • Must sign a written Informed Consent form and be willing to undergo cataract surgery for the implantation of an IOL with random assignment to either the RxSight

LAL or the monofocal control IOL.

• Between the ages of 40 and 80 inclusive on the day the cataract surgery is performed.

• Preoperative corneal cylinder greater than or equal to 0.75 diopters (D) to =2.00 D or >2.00 D and < 2.5 D

of corneal cylinder with a steep axis between 70 degrees and 110 degrees.

• Study eye has best corrected distance visual acuity projected (by clinical estimate based upon past ocular history and retinal exam) to be 20/20 or better after cataract removal and IOL implantation.

• Study eye has clear intraocular media other than cataract.

• Willing and able to comply with the requirements for study specific procedures and visits.

• Study eye has average dilated pupil diameter of greater than or equal to 7.0 mm.

• Able to complete a written questionnaire in English.

• Study eye requires an IOL power within the range available for the RxSight LAL.
Sample Size Phase A – 24 English speaking patients in the EU at 1-3 sites

Phase B – 500 subjects at 10 sites randomized 2:1 to receive either a RxSight LAL (333 eyes) or monofocal control (167 eyes). Only one eye per subject may be included in the study. Calculation is based on the two primary safety endpoints described below.

Data Collection The primary effectiveness endpoints are:



Mean absolute manifest refraction spherical equivalent (|MRSE|) at postop month 6 compared between the RxSight LAL and Control group



Mean manifest cylinder at postop month 6 compared between the RxSight LAL and Control group



The primary safety endpoints are:



Mean rate of endothelial cell density loss at postop month 6 compared to preoperatively compared between the RxSight LAL and Control group



Percent of RxSight LAL eyes with UV retinal damage at postop month 6





Follow-up Visits and Length of Follow-up 6 months minimum, except in cases where UV retinal damage is confirmed then 12 months minimum.
Interim or Final Data Summary
Interim Safety Information Not reported
Actual Number of Patients Enrolled Not reported
Actual Number of Sites Enrolled Not reported
Patient Follow-up Rate Not reported
Study Strengths & Weaknesses This information will be included in the final report


LAL/LDD Postmarket RCT Schedule

Report Schedule
Report
Date Due
FDA Receipt
Date
Applicant's Reporting Status
six month report 05/23/2018 06/19/2018 Overdue/Received
one year report 09/04/2019 08/28/2019 On Time
18 month report 03/04/2020 02/27/2020 On Time
two year report 09/04/2020 09/01/2020 On Time
30 month report 03/04/2021 03/02/2021 On Time
three year report 09/04/2021    
final report 03/29/2024    


Contact Us

Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources

-
-